Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 9/20 | 0.77 |
| ▸ | RAB9A | P51151 | 9/20 | 0.77 |
| ▸ | MEN1 | O00255 | 7/20 | 0.77 |
| ▸ | KMT2A | Q03164 | 7/20 | 0.77 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.77 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.67 |
| ▸ | MAPT | P10636 | 3/20 | 0.67 |
| ▸ | LMNA | P02545 | 2/20 | 0.67 |
| ▸ | HTT | P42858 | 2/20 | 0.67 |
| ▸ | GFER | P55789 | 1/20 | 0.67 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.64 |
| ▸ | TP53 | P04637 | 3/20 | 0.61 |
| ▸ | CASP3 | P42574 | 1/20 | 0.61 |
| ▸ | CASP2 | P42575 | 1/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.58 |
| ▸ | GAA | P10253 | 1/20 | 0.58 |
| ▸ | THRB | P10828 | 1/20 | 0.58 |
| ▸ | HPGD | P15428 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8888157 | 0.86 | NPC1 (0.75) | NPC1RAB9AMEN1KMT2ATDP1 | |
| SCHEMBL834778 | 0.83 | SMN1; SMN2 (0.65) | NPC1RAB9AMEN1KMT2ATDP1 | |
| SCHEMBL19392293 | 0.83 | NPC1 (0.89) | NPC1RAB9AMEN1KMT2ATDP1 | |
| SCHEMBL8771200 | 0.83 | NPC1 (0.89) | NPC1RAB9AMEN1KMT2ATDP1 | |
| SCHEMBL2063276 | 0.81 | NPC1 (0.86) | NPC1RAB9AMEN1KMT2ATDP1 | |
| SCHEMBL1929165 | 0.81 | NPC1 (0.85) | NPC1RAB9AMEN1KMT2ATDP1 | |
| SCHEMBL4715529 | 0.81 | NPC1 (0.49) | NPC1RAB9AMEN1KMT2ATDP1 | |
| SCHEMBL7717513 | 0.80 | MEN1 (1.00) | NPC1RAB9AMEN1KMT2ATDP1 | |
| SCHEMBL22804218 | 0.80 | NPC1 (0.83) | NPC1RAB9AMEN1KMT2ATDP1 | |
| SCHEMBL12495837 | 0.80 | NPC1 (1.00) | NPC1RAB9AMEN1KMT2ATDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8143410-B2 | Kinase inhibitors | ALLERGAN, INC. (US) | 2012-03-27 | — | — | US | disclosed |
| US-20110263611-A1 | Kinase Inhibitors | ALLERGAN, INC. | 2011-10-27 | — | — | US | disclosed |
| US-7915443-B2 | Sulfoximines as kinase inhibitors | ALLERGAN, INC. (US) | 2011-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110263611-A1 | Kinase Inhibitors | PTK2, MAP3K6, MAP3K20 | NPC1 4757/4885RAB9A 2105/4885MEN1 3831/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.